Literature DB >> 8947989

Variability in zidovudine serum concentrations.

C V Fletcher1, H H Balfour.   

Abstract

This study explored the variability of zidovudine concentrations with computer simulations and measured concentrations. A one-compartment oral absorption model was selected to characterize zidovudine disposition. Mean (+/-standard deviation) values for the pharmacokinetic parameters were taken from the literature. Five different Monte Carlo simulations (50 each) were performed of zidovudine concentrations following repetitive administration of 100-mg oral doses 6 times/day in patients weighing 45-85 kg. A sixth simulation considered a weight-adjusted regimen. Predicted concentrations were compared with those measured in 30 HIV-infected persons receiving 100 mg/dose. Predicted concentrations 1 hour after 100 mg was administered fell in the range of 0.52-5.18 microM; measured values in 30 patients were 0.54-3.07 microM. This study confirms substantial variability in zidovudine serum concentrations. The simulation study of a weight-adjusted regimen suggests one possibility to reduce this variability. These observations provide a basis to explore dosing strategies that control for pharmacokinetic and perhaps pharmacodynamic sources of interpatient variability.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8947989

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

1.  Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.

Authors:  T N Kakuda; L M Page; P L Anderson; K Henry; T W Schacker; F S Rhame; E P Acosta; R C Brundage; C V Fletcher
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis?

Authors:  Offie Porat Soldin; Ronald J Elin; Steven J Soldin
Journal:  Arch Pathol Lab Med       Date:  2003-01       Impact factor: 5.534

3.  Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?

Authors:  Floris Fauchet; Jean-Marc Treluyer; Elodie Valade; Sihem Benaboud; Emmanuelle Pannier; Ghislaine Firtion; Frantz Foissac; Naim Bouazza; Saik Urien; Déborah Hirt
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of zidovudine. An update.

Authors:  E P Acosta; L M Page; C V Fletcher
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

Review 5.  Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

Authors:  Nila Bhana; Douglas Ormrod; Caroline M Perry; David P Figgitt
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children.

Authors:  Floris Fauchet; Jean-Marc Treluyer; Pierre Frange; Saik Urien; Frantz Foissac; Naim Bouazza; Sihem Benaboud; Stephane Blanche; Déborah Hirt
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.